GlassScriptPhysician profile
Joshua Lee
NPI 1770853418
$5,838.02
in general payments reported to CMS, 2019-2025
25 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.06 · 2020: $307 · 2021: $109 · 2022: $499 · 2023: $787 · 2024: $2,615 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,150 · Travel and Lodging: $1,553 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.86 |
| Travel and Lodging | $1,553.09 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Transmedics, INC. | $1,553.09 | 2024 | Organ Care System |
| Glaxosmithkline, LLC. | $1,095.14 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astellas Pharma US INC | $465.36 | 2023-2025 | Cresemba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.84 | 2020-2024 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Insmed, INC. | $345.63 | 2023-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $318.97 | 2024-2025 | Tyvaso, Orenitram, Remodulin |
| Astrazeneca Pharmaceuticals LP | $289.66 | 2020-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $244.22 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $232.99 | 2023-2025 | Winrevair |
| Takeda Pharmaceuticals U.S.A., INC. | $140.77 | 2021-2025 | Livtencity, Hyqvia, Glassia |
| Viatris Specialty LLC | $137.88 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $124.63 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.33 | 2022-2025 | |
| Eurofins Viracor, LLC | $86.69 | 2024 | |
| Vifor Pharma, INC. | $51.00 | 2024 | Zemaira |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33.48 | 2024 | Wegovy |
| Pharming Healthcare, INC. | $33.02 | 2023 | Ruconest |
| Ani Pharmaceuticals, INC. | $27.27 | 2024-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $23.49 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Pulmonx Corporation | $22.91 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Advanced Respiratory, INC | $20.63 | 2020 | |
| Electromed, INC. | $17.67 | 2025 | Smartvest |
| Invivyd INC | $17.67 | 2025 | Pemgarda |
| Mallinckrodt Hospital Products INC. | $16.68 | 2024 | Acthar |
| Daiichi Sankyo INC. | $15.00 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.